Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.

A short instructional video that demonstrates how to prepare and deliver Cosentyx injections. 

Do not share links to this Novartis Healthcare Professional website or screenshots with patients as this website is intended for healthcare professionals only. 

If you do wish to share an injection video with patients, please share this link:

health.novartis.co.uk/public/dermatology/cosentyx/patient-resources/unoreadyr-300mg-injection-video

 

 

 

Click here for Cosentyx (secukinumab) prescribing information

CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs.

 

UK | April 2021 | 117276
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]